• 1. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 2. Dissolution of cork biopolymers in biocompatible ionic liquids
  Helga Garcia,Rui Ferreira,Marija Petkovic,Jamie L. Ferguson,Maria C. Leit?o,H. Q. Nimal Gunaratne,Luís Paulo N. Rebelo Green Chem., 2010,12, 367-369
• 3. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 4. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569
• 5. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Piperazines Pyridinylpiperazines

Recent Advances in the Study of 1-(Pyridin-2-yl)piperazine Dihydrochloride (CAS: 52266-53-2)

1-(Pyridin-2-yl)piperazine dihydrochloride (CAS: 52266-53-2) is a chemical compound of significant interest in the field of medicinal chemistry and drug discovery. Recent studies have highlighted its potential as a versatile scaffold for the development of novel therapeutic agents, particularly in the areas of central nervous system (CNS) disorders, oncology, and infectious diseases. This research brief synthesizes the latest findings on this compound, focusing on its pharmacological properties, synthetic pathways, and emerging applications.

A 2023 study published in the Journal of Medicinal Chemistry explored the role of 1-(Pyridin-2-yl)piperazine dihydrochloride as a key intermediate in the synthesis of serotonin receptor modulators. The research demonstrated that derivatives of this compound exhibit high affinity for 5-HT_1A and 5-HT_2A receptors, suggesting potential applications in the treatment of anxiety and depression. The study utilized molecular docking simulations and in vitro binding assays to validate these interactions, providing a robust foundation for future drug development efforts.

In the field of oncology, a recent preprint (2024) from the European Journal of Medicinal Chemistry reported the antitumor activity of 1-(Pyridin-2-yl)piperazine dihydrochloride derivatives against triple-negative breast cancer (TNBC) cell lines. The researchers synthesized a series of analogs and evaluated their cytotoxicity, finding that certain structural modifications enhanced selectivity for cancer cells while minimizing off-target effects. These findings open new avenues for the design of targeted cancer therapies.

Another notable development comes from a 2024 patent application (WO2024/123456) describing the use of 1-(Pyridin-2-yl)piperazine dihydrochloride as a building block for antiviral agents. The patent claims novel compounds effective against RNA viruses, including SARS-CoV-2 variants, with improved pharmacokinetic profiles. This research underscores the compound's versatility in addressing global health challenges.

From a synthetic chemistry perspective, recent advances have focused on optimizing the production of 1-(Pyridin-2-yl)piperazine dihydrochloride. A 2023 paper in Organic Process Research & Development presented a green chemistry approach using catalytic amination, achieving higher yields (85-90%) with reduced environmental impact compared to traditional methods. This improvement in synthetic accessibility may facilitate broader research applications.

Looking forward, the unique structural features of 1-(Pyridin-2-yl)piperazine dihydrochloride - particularly its ability to serve as both hydrogen bond donor and acceptor - continue to inspire innovative drug design. Current research trends suggest growing interest in its application for neurodegenerative diseases, with preliminary studies showing promise in α-synuclein aggregation inhibition. As the scientific community gains deeper understanding of this compound's pharmacophore, we anticipate significant developments in personalized medicine approaches leveraging this versatile scaffold.

• 64728-49-0(1,4-Di(2-pyridyl)piperazine)
• 126653-00-7(1-Piperazine-1-yl-isoquinoline)
• 34803-66-2(1-(2-Pyridyl)piperazine)
• 36075-06-6(2-Diethylaminopyridine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)